Alzheimer's disease, the leading cause of dementia, has thwarted medical advancements for decades. A groundbreaking study published in January in the journal Nature reveals that the APOE gene significantly influences Alzheimer's risk, opening new avenues for gene therapy to potentially correct it. With 99% of the population carrying at least one disease-fueling version of the gene, this finding has profound implications for the 6.7 million Americans living with Alzheimer's and the millions more at risk.
- The APOE gene plays a crucial role in determining Alzheimer's risk, with 72-93% of cases linked to specific variants.
- Gene therapy targeting APOE variants offers a promising new approach to treating Alzheimer's disease.
- Current Alzheimer's treatments have severe side effects, making gene therapy a potentially safer alternative.
- Lexeo Therapeutics is conducting clinical trials to test APOE gene therapies in patients with early Alzheimer's.
- APOE gene therapies could benefit a vast number of people, potentially revolutionizing Alzheimer's treatment.
How the APOE Gene Influences Alzheimer's Risk
The APOE gene has three main variants: APOE2, APOE3, and APOE4. Each variant codes for a slightly different version of the APOE protein, which plays a crucial role in transporting fat molecules through the bloodstream. However, the APOE protein also interacts closely with amyloid-beta, a protein that aggregates into plaques, destroying neuronal connections and triggering inflammation in the brain.
Previous research suggested that APOE2 was protective, while APOE4 increased Alzheimer's risk. APOE3 was thought to be neutral. However, a new study analyzing data from 450,000 individuals revealed that APOE3 also increases Alzheimer's risk, albeit to a lesser extent than APOE4. Carrying two copies of APOE2 makes individuals almost immune to developing Alzheimer's, while APOE4 significantly impairs fat processing in glial cells, increases cell death, and hampers synaptic plasticity.
APOE Variants and Alzheimer's Prevalence
The study found that APOE3 and APOE4 together are responsible for between 72% and 93% of Alzheimer's disease cases. This means that without the underlying risks from these variants, nearly all Alzheimer's cases and half of all dementia cases would not occur. The protective nature of APOE2 was further confirmed by a 2020 study, which found that individuals with two copies of APOE2 have a 200 times lower risk of developing Alzheimer's than those with two copies of APOE4.
The Role of Gene Therapy in Treating Alzheimer's
Gene therapy has already transformed the lives of people with rare genetic disorders, such as spinal muscular atrophy (SMA) and retinal dystrophy. However, these treatments target small populations. Alzheimer's, with its vast impact, presents a unique challenge. About 28% of the population carries at least one copy of the highest-risk versions of the APOE gene, making it a potential target for gene therapy.
Lexeo Therapeutics, based in New York City, is at the forefront of developing APOE gene therapies. The company plans to conduct three safety and dosing clinical trials to increase protective APOE gene variants and reduce harmful APOE gene variants in people with the highest-risk gene combination, APOE4/APOE4, who have early Alzheimer's disease.
Clinical Trials and Therapeutic Approaches
The first phase of Lexeo's research involves a combined safety and dosing study that incorporates the protective APOE2 gene variant into the brains of people with early Alzheimer's. A second study will introduce a version of APOE2 with the Christchurch mutation, a rare variant found in individuals who show no Alzheimer's symptoms despite severe amyloid plaque buildup. The third trial will combine the addition of APOE2 with using RNA snippets to suppress APOE4 gene expression.
Challenges and Regulatory Hurdles
While gene therapies targeting APOE variants hold promise, several challenges remain. Pharmaceutical companies must choose a clinical outcome to demonstrate to regulators that their therapies work. Behavioral and cognitive testing, while ideal, are expensive and time-consuming. Additionally, the regulatory environment for genetic therapies is less permissive than for other treatments, such as anti-amyloid antibodies.
Another challenge is delivering the gene therapy to the brain cells that need it. Adeno-associated viruses (AAVs) have been the vector of choice, but scientists are still working on maximizing blood-brain barrier penetrance. Lexeo has opted to deliver its gene therapy into the cerebrospinal fluid, which circulates through the spinal cord, improving brain-wide delivery.
The Future of APOE Gene Therapies
Despite the challenges, gene therapies targeting APOE variants have excited the field due to their potential to benefit a vast number of people. Dr. Shanshan Wang, an anesthesiologist at the University of California, San Diego, emphasizes the importance of combinatory treatments, much like cancer therapies that target multiple disease facets simultaneously.
As research continues to uncover the complexities of Alzheimer's disease, gene therapy offers a glimmer of hope. By targeting the APOE gene, scientists may finally be able to develop effective treatments for this devastating condition, improving the lives of millions of people worldwide.
Frequently Asked Questions
- What is the APOE gene and how does it affect Alzheimer's risk?
- The APOE gene has three main variants: APOE2, APOE3, and APOE4. APOE4 is the highest-risk variant, significantly increasing the likelihood of developing Alzheimer's. APOE2 is protective, while APOE3 increases risk to a lesser extent.
- How does gene therapy work for Alzheimer's disease?
- Gene therapy for Alzheimer's involves delivering healthy APOE gene variants or suppressing harmful variants to brain cells. This approach aims to correct the underlying genetic factors that increase Alzheimer's risk.
- What are the challenges in developing APOE gene therapies?
- Challenges include choosing a clinical outcome to demonstrate efficacy, delivering the therapy to the brain cells, and navigating the regulatory environment. Additionally, behavioral and cognitive testing are expensive and time-consuming.
